Skip to main content

In the treatment of adults and adolescents with uncontrolled moderate-to-severe atopic dermatitis

Results from 3 real-world studies

Real-world persistency and patient satisfaction at 5 years1

RELIEVE-AD 18+ YEARS

Persistency and satisfaction at 5 years1

74% OF PATIENTS
treated with
DUPIXENT remained
on therapya
At Month 60, 26% of patients had
discontinued therapy with DUPIXENT
87% OF PATIENTS
were very/extremely/
somewhat satisfied
with
their overall AD treatment at
Month 60 (286 of 329)
Before starting DUPIXENT, 18% of patients
were very/extremely/somewhat satisfied with
their overall AD treatment

RELIEVE-AD STUDY DESIGN: RELIEVE-AD is a single-arm, prospective, observational study in patients with moderate-to-severe atopic dermatitis enrolled in DUPIXENT MyWay® prior to initiating treatment with DUPIXENT. Patients completed multiple surveys over 60 months. At Month 60, participants that responded to the survey at Month 33 and/or Month 48 were recontacted for Month 60 follow-up.1,2

Limitations of analysis: This patient population was self-selected; those who maintain long-term efficacy and safety may be more likely to participate in such surveys. Similarly, patients were recruited through a DUPIXENT patient support program, which may influence patient perceptions of treatment benefit.1,2

aPercentages calculated as total patients who permanently discontinued DUPIXENT from Month 1 up until each month subtracted from the number of patients who started treatment at baseline (N=471). From Month 1 through Month 60, 122 patients permanently discontinued DUPIXENT. In addition, 39 patients discontinued DUPIXENT and restarted at a later time point at least once.

IBM MARKETSCAN 18+ YEARS
77% of adult patients treated with DUPIXENT remained on therapy at 1 year3
Of the patients who discontinued therapy at 1 year
≈8 OF 10
patients returned to DUPIXENT
treatment within 4 months3

IBM MARKETSCAN STUDY DESIGN: From IBM MarketScan Commercial and Medicare supplemental databases, 1963 adults were identified who initiated DUPIXENT between March 28, 2017, and March 31, 2018, and followed until September 30, 2018, or disenrollment. Patients received a mean of 8.6 DUPIXENT dispensations from initiation to first discontinuation.3

Limitations of analysis: Kaplan-Meier analysis was used to estimate persistence at 6 and 12 months, assuming a 14-day injection frequency. Limitations of this study may be the potential misclassification of patients in claims-based analyses that rely on International Classification of Disease (ICD) diagnostic codes for population identification. Study included only early initiators of DUPIXENT, which likely reflects more severe patients, potentially reducing generalizability since persistence may be different in a more diverse population of patients who initiate DUPIXENT. Duration of treatment and persistence was based on assumptions about whether and how patients take their treatment, and such assumptions may result in misclassification that could potentially over- or underestimate persistence.3

Real-world results in skin improvement at 4 years4

RETROSPECTIVE DYNAMIC
COHORT STUDY 18+ YEARS
EASI-90 and EASI-75
AT 4 years4

RETROSPECTIVE DYNAMIC COHORT STUDY DESIGN: In this retrospective, multicenter, Italian dynamic cohort study, data on 2576 adult patients with moderate-to-severe atopic dermatitis treated with DUPIXENT were collected from 24 dermatological centers from June 2018 to July 2022. Data are from patients observed at 4 months (N=2364), 12 months (N=2066), 24 months (N=1291), 36 months (N=601), and 48 months (N=110).4

Limitations of analysis: Limitations include the retrospective nature of the study and dynamic cohort design that hindered considerations regarding drug survival. Patients were also treated with other atopic dermatitis medications.4

Disease severity at 3 years5

PROSE 12+ YEARS

Results at 3 years

73%
mean improvement
in Peak Pruritus
NRS score
Mean Peak Pruritus NRS score was 7.1
at baseline
(n=622) and 1.9 at 3 years
(n=135)
86%
mean
improvement
in EASI score
Mean EASI score was 16.2 at baseline
(n=854) and 2.2 at 3 years (n=148)

PROSE STUDY DESIGN: PROSE is an ongoing, longitudinal, prospective, observational registry in the USA and Canada (NCT03428646) of patients aged
≥12 years with moderate-to-severe atopic dermatitis, treated with DUPIXENT in accordance with approved prescribing information (N=857; data presented
include 55 adolescents aged ≥12 to <18 years). Data presented here are from an interim analysis with a data cut taken as of June 15, 2022.5,6

Limitations of analysis: Patients were also treated with other atopic dermatitis medications. While the initial prescription for DUPIXENT had to be in accordance with approved prescribing information, physicians were free thereafter to make any treatment decisions they deemed appropriate. Also, there could be a bias toward better outcomes in patients who continue providing data in this real-world study.5,6

CLINICAL TRIAL DESIGNS
AND RESULTS IN ADULTS AND ADOLESCENTS